Skip to content

Author

Reza Arsanjani

6 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Nov 2026

Abstract 18075: Cardiovascular Events and Mortality After KRAS Inhibitor Therapy Discontinuation in Patients with Non-Small Cell Lung Cancer

Background: KRAS inhibitors, including Sotorasib and Adagrasib, have expanded treatment options for patients with KRAS-mutated non small cell lung cancer (NSCLC). However, cardiovascular outcomes after KRAS inhibitor initiation remain poorly characterized. Hypothesis: We hypothesized that cardiovascular events...

Amal Youssef, Cecilia Villa Etchegoyen, Sherif Ahmed et al. · 0 citations
Open access Oct 2026

Sodium–Glucose Cotransporter-2 Inhibitors in World Health Organization Group 1 Pulmonary Arterial Hypertension: A REVEAL Lite 2–Matched Cohort With Time-Varying Exposure Analysis

Sodium–glucose cotransporter-2 inhibitors (SGLT2i) improve outcomes across several cardiometabolic conditions, but their role in World Health Organization group 1 pulmonary arterial hypertension (PAH) remains uncertain. We conducted a retrospective, single-center cohort study of adults with group 1 PAH. Patients prescr...

Abdelrahman Hafez, Amal Youssef, Mohamed Nour et al. · 0 citations
Open access Oct 2026

Association of the Red Cell Distribution Width–Albumin Ratio with Myocardial Strain, Mortality, and Heart Failure Hospitalization: A Retrospective Cohort Study

A higher RAR was associated with abnormal LVGLS, HF hospitalization, and all-cause mortality after adjustment for clinical risk factors, but the RAR did not provide discriminative value beyond its individual components.

Sherif Ahmed, K. Awad, Abdelrahman Hafez et al. · 0 citations
Review Open access Oct 2026

Epigenetic vs chronologic age for cardiovascular risk assessment

Chronological age is a dominant determinant of cardiovascular risk prediction. However, DNA methylation-derived epigenetic clocks capture biological aging processes that may reflect cumulative cardiometabolic and inflammatory exposures. Whether biological age improves contemporary cardiovascular risk estimation,...

R. Ibrahim, B. Tamarappoo, K. Lee et al. · 0 citations
Sep 2026

From Image Interpretation to Clinical Reasoning: Upstream Physician-Context-Aware Multimodal Learning with Causal Reinforcement Learning

Major adverse cardiovascular events (MACE) remain the leading cause of mortality worldwide. Opportunistic screening using routinely acquired clinical data offers a scalable approach for identifying high-risk individuals before acute events occur. Although chest X-rays (CXRs) capture latent cardiovascular biomarkers and...

Jia-Lu Pi, Ya-Nan Ma, Wei-Jie Chen et al. · 0 citations
Review Aug 2026

Assessing Differences Between Epigenetic versus Chronologic Age for Cardiovascular Risk Assessments in the United States.

Biologic PREVENT variants were associated with mortality but did not improve discrimination compared with chronologic PREVENT, suggesting biological aging metrics may complement rather than replace chronological age in cardiovascular risk prediction.

Ramzi Ibrahim, B. Tamarappoo, Kwan S. Lee et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.